Nebivolol Accord (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic antagonist used primarily in the management of arterial hypertension and related cardiovascular conditions.

• Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.
• Heart failure with reduced ejection fraction: improves cardiac output and may reduce hospitalization risk.
• Left ventricular hypertrophy: may slow progression of structural heart changes associated with high blood pressure.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which lowers cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide release, causing vasodilation and further contributing to antihypertensive effects without significant β2 blockade.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially after standing.
• Fatigue or tiredness.
• Bradycardia: slower than normal heart rate.
• Nausea or mild gastrointestinal upset.
• Nasal congestion.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Acute bronchospasm in patients with asthma or COPD.
• Allergic reactions such as rash, itching, or angioedema.
• Hepatic dysfunction or elevated liver enzymes.
• Marked hypotension leading to syncope.
• Cardiovascular collapse in overdose.

Before initiating Nebivolol therapy, clinicians should consider several safety measures.

• Monitor blood pressure: ensure adequate control and avoid excessive drops.
• Assess cardiac function: evaluate heart rate and ECG for bradyarrhythmias.
• Use caution in asthma or chronic obstructive pulmonary disease: risk of bronchospasm.
• Avoid abrupt discontinuation: taper dose to prevent rebound hypertension.
• Adjust dose in renal impairment: consider reduced clearance.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other beta‑blockers: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): increased risk of AV block.
• Strong CYP2D6 inhibitors (paroxetine, fluoxetine): elevated Nebivolol plasma levels.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect.
• Diuretics: potential for excessive blood pressure reduction.
• ACE inhibitors or ARBs: monitor for additive hypotensive effect.
• Clonidine: risk of rebound hypertension if stopped abruptly.